Bright Minds Biosciences Inc. (DRUG)
- Previous Close
33.00 - Open
32.61 - Bid --
- Ask --
- Day's Range
31.26 - 33.90 - 52 Week Range
0.93 - 79.02 - Volume
31,581 - Avg. Volume
35,316 - Market Cap (intraday)
225.337M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.14 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
93.27
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
brightmindsbio.comRecent News: DRUG
View MorePerformance Overview: DRUG
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRUG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRUG
View MoreValuation Measures
Market Cap
227.89M
Enterprise Value
186.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.93%
Return on Equity (ttm)
-3.34%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.07M
Diluted EPS (ttm)
-0.14
Balance Sheet and Cash Flow
Total Cash (mrq)
57.9M
Total Debt/Equity (mrq)
0.32%
Levered Free Cash Flow (ttm)
-1.4M